ライフサイエンスコーパス: clinical study

1 igen of coronaviruses, which is currently in clinical study.

2 viral effect against RSV, warranting further clinical study.

3 ver one year in the placebo arm of the SOLVD clinical study.

4 performance of the BCID-FP in a multicenter clinical study.

5 is potential should be explored further in a clinical study.

6 sed on DNAzyme technology as candidates to a clinical study.

7 n-regulated investigational device exemption clinical study.

8 through future research, patient input, and clinical study.

9 treatments that merit further molecular and clinical study.

10 ) derived from participants of a prior E2-WD clinical study.

11 (multidrug and toxin extrusion proteins) in clinical studies.

12 e may inform future management protocols and clinical studies.

13 ng LPA technology, calling for dedicated pre-clinical studies.

14 ical models that also might be applicable to clinical studies.

15 nd serves as an important starting point for clinical studies.

16 therapy (PTT) has shown promising results in clinical studies.

17 demonstrated in both animal models and human clinical studies.

18 l cultures or for external-beam radiotherapy clinical studies.

19 drug target, with inhibitors progressing to clinical studies.

20 n strength, as seen in other preclinical and clinical studies.

21 nal tool for evaluating treatment effects in clinical studies.

22 umber of compounds that can be advanced into clinical studies.

23 tended profile of LRRK2 kinase modulation in clinical studies.

24 guide new applications in both cellular and clinical studies.

25 ule, which is ready for use in international clinical studies.

26 ot be used alone to determine event rates in clinical studies.

27 ase was generated from published in vivo and clinical studies.

28 y infections in a variety of preclinical and clinical studies.

29 iated with incident CVD risks in large-scale clinical studies.

30 gestation period and birth timing, and human clinical studies.

31 trials for advanced HCC patients without pre-clinical studies.

32 the optimization of preclinical research and clinical studies.

33 ient data is available, as is often found in clinical studies.

34 ce of CrCP contribution in physiological and clinical studies.

35 cohort study of PLWH from 7 HIV clinics or 4 clinical studies.

36 trating the utility of technique in food and clinical studies.

37 branebrutinib, BMS-986195) has advanced into clinical studies.

38 stratifying subjects for epidemiological and clinical studies.

39 and increased proinflammatory macrophages in clinical studies.

40 emphasis on the findings of the most recent clinical studies.

41 ffect has been confirmed in experimental and clinical studies.

42 effective research translation from bench to clinical studies.

43 se, as well as advances in imaging and other clinical studies.

44 f dynamic CA efficiency in physiological and clinical studies.

45 n may be a functional outcome measure in AMD clinical studies.

46 ith the longitudinal data from two published clinical studies.

47 We consider the use of markers of NETs in clinical studies.

48 number events in a cost-effective manner in clinical studies.

49 should be evaluated in further prospective, clinical studies.

50 useful as an adjuvant therapy in future pre-clinical studies.

51 tegy that should be developed further in pre-clinical studies.

52 in biological research, drug discovery, and clinical studies.

53 chenodeoxycholic acid) has shown promise in clinical studies.

54 translational bridge between preclinical and clinical studies.

55 diovascular function in both preclinical and clinical studies.

56 zolopyrimidine DSM265 (1) showed efficacy in clinical studies.

57 were largely concordant with cross-sectional clinical studies.

58 ncreased power in experimental, genetic, and clinical studies.

59 llenges of establishing NMP programs outside clinical studies.

60 frequency evaluation to be tested in future clinical studies.

61 ) transcriptomes in diverse experimental and clinical studies.

62 In the clinical study, 24 in vivo-in vitro pairs were eligible

63 Recent population-based(1-4) and clinical studies(5) have identified a range of factors a

64 In this phase III prospective multicenter clinical study, 795 patients with known or suspected CAD

65 technology during preclinical and especially clinical studies about biologic drug formats and disease

66 n, with implications for epidemiological and clinical studies across the life-span.

67 esis could lead to basic, translational, and clinical studies aimed at reducing COVID-19 morbidity an

68 Preclinical and clinical studies aiming to broaden the therapeutic appli

69 In this prospective clinical study, an oral glucose tolerance test (OGTT) an

70 We conducted a literature search to identify clinical studies and case series of surgically managed O

71 We will also summarize ongoing clinical studies and discuss the challenges associated w

72 nections, so as to enable comparisons across clinical studies and for basic scientists to probe mecha

73 trium reconnections are consistently seen in clinical studies and in clinical practice as operators a

74 sculoskeletal defects in AD come from recent clinical studies and include potential underlying mechan

75 rts, including retrospective and prospective clinical studies and patient series.

76 sk for depression is controversial; however, clinical studies and randomized placebo-controlled trial

77 Well-designed and well-conducted clinical studies and registries are needed to more preci

78 The search was restricted to clinical studies and relevant grey literature published

79 he feasibility of respirometry in multi-site clinical studies and retrospective studies.

80 that nOPV2 is immunogenic in preclinical and clinical studies, and thus may enable complete polioviru

81 onal data collection, expert discussion, and clinical studies are critical to informing evidence-base

82 de-based antitumour vaccines being tested in clinical studies are generally associated with weak pote

83 n (CDI) diagnostics, and further prospective clinical studies are merited.

84 Further clinical studies are necessary to evaluate the maximum t

85 Long-term clinical studies are necessary to reach final conclusion

86 Unfortunately results from clinical studies are not convincing.

87 Clinical studies are required to assess whether a simila

88 neous delivery of OS2966 and now preclinical/clinical studies are required to demonstrate therapeutic

89 Further clinical studies are required to test the suitability of

90 l importance, more well-designed in-vivo and clinical studies are required.

91 n previously thought, whereas scientific and clinical studies are starting to fundamentally challenge

92 Five additional clinical studies are underway or in development.

93 Several clinical studies are underway that test the effects of i

94 Rigorously designed preclinical and clinical studies are warranted.

95 ndividuals with type 2 diabetes as part of a clinical study assessing the occupancy of the dual GCGR/

96 As in clinical studies, attentional bias was indicated by elon

97 We identified 4 recent clinical studies based on nationwide databases of high q

98 The developed algorithm could facilitate clinical studies by supporting high-throughput automated

99 Food allergy diagnosis in clinical studies can be challenging.

100 More and more clinical studies, cancer cell lines studies, CRISPR scre

101 season and continued during the season in 40 clinical study centers in 5 European countries.

102 Clinical studies combining radiation and immunotherapy h

103 This observational clinical study compared morphologic and functional chang

104 al search of literature was made to identify clinical studies comparing early implant placement with

105 the GLOBAL LEADERS trial (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-Platelet Ther

106 However, clinical studies demonstrate that increased RAGE ligands

107 nd thus associated with tumor cell invasion, clinical studies demonstrated increased expression of TI

108 The initial clinical study demonstrated that this non-invasive test

109 There is much evidence from controlled clinical studies demonstrating that SFAs increase LDL ch

110 INFORM-RSV is a multiyear clinical study designed to describe the global molecular

111 requires an understanding of differences in clinical study designs and the various statistical metho

112 at clinicians understand how the comparative clinical study differs from a traditional phase III effi

113 g screening procedures for a 3-day inpatient clinical study during which 24-h BP measurements were ob

114 More importantly, recent clinical studies emphasized in situ neurovascularization

115 vents with CTLA4 and PD1 pathway blockade in clinical studies, especially in combination therapy grou

116 pressures and confound the interpretation of clinical studies, especially in the case of trials invol

117 More clinical studies, especially randomized controlled trial

118 rrants additional testing in preclinical and clinical studies, especially since 2'FL and LNnT are amo

119 After receiving approval from the clinical studies Ethics Committee, magnetic resonance im

120 This randomized clinical study evaluated 41 patients at 3 years follow-u

121 This Phase 2 clinical study evaluated the efficacy and safety of VT-1

122 ment of brolucizumab and the preclinical and clinical studies evaluating its efficacy, tolerability,

123 eting properties of DOTA-MGS5 support future clinical studies evaluating the diagnostic and therapeut

124 Our data may open for clinical studies exploring a new possible strategy to pr

125 LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and S

126 rticular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.

127 eview various lines of evidence derived from clinical studies for dynorphin and kappa opioid receptor

128 ctor (TNF) polyclonal antibody used in early clinical studies for treatment of ulcerative colitis, us

129 dulator that has been evaluated in a phase 2 clinical study for the treatment of Duchenne muscular dy

130 Clinical studies frequently report that patients with ma

131 on-dependent effects for cancer treatment in clinical studies, functional genomics studies and comput

132 Significantly, clinical studies further confirm the activated c-Myc-miR

133 standardizing CMR protocols for research and clinical studies has become important in order to optimi

134 A framework for systematic clinical studies has been created by the development of

135 A growing body of clinical studies has documented a correlation between le

136 Clinical studies have also reported an association betwe

137 Clinical studies have also reported that HSV-1 causes po

138 Hundreds of clinical studies have been registered with the intention

139 To date, only a few small clinical studies have been reported and most data are de

140 e last decade, a plethora of preclinical and clinical studies have confirmed the efficacy of ketamine

141 Recent clinical studies have demonstrated that lacosamide, whic

142 Preclinical and clinical studies have demonstrated that systemic restric

143 Numerous clinical studies have demonstrated the negative effect o

144 Recent pre-clinical studies have demonstrated the potential of comb

145 Past and ongoing clinical studies have demonstrated the safety of cell th

146 Numerous animal and clinical studies have examined MP therapeutic agents, so

147 No pre-clinical studies have explored the effects on skeletal m

148 Recent clinical studies have measured regional stiffness within

149 Clinical studies have observed an unexpected improvement

150 ram (EEG) and functional imaging measures in clinical studies have previously investigated the neural

151 Previous clinical studies have reported adverse cognitive outcome

152 Clinical studies have reported that epicardial adipose t

153 Most clinical studies have shown no beneficial effect of anti

154 However, clinical studies have so far been disappointing.

155 omising results in preclinical tumor models, clinical studies have so far shown only little efficacy.

156 Recent animal and small clinical studies have suggested depression is related to

157 Clinical studies have suggested that changes in peripher

158 Clinical studies have validated that antiretroviral (ARV

159 appropriate controls and analyses for future clinical studies, here we analyze data collected from he

160 Clinical studies hint that pharmaceutical therapy may be

161 provement in visual and anatomic outcomes in clinical studies in a q12-week regimen, indicating its p

162 Here, we review the role of comparative clinical studies in biosimilar development, with a focus

163 al features, as supported by data from pilot clinical studies in both the NICU and PICU.

164 effects, making them easier to fast-track to clinical studies in COVID-19 patients.

165 and the power of combining pre-clinical and clinical studies in efforts to improve HCC immunotherapy

166 Clinical studies in individuals with painful knee and hi

167 treated for Plasmodium falciparum malaria in clinical studies in Myanmar or on the Thailand-Myanmar b

168 Evidence from mouse models and early clinical studies in patients with ALD injury supports th

169 E, and can inform additional preclinical and clinical studies in RCC.

170 Clinical studies in recent months have revealed that COV

171 given the lack of well-designed contemporary clinical studies in the field.

172 ion of allogeneic EVs for therapeutic use in clinical studies in which an adaptive immune response is

173 did a non-randomised, open-label, phase 1/2 clinical study in paediatric patients with severe Wiskot

174 t is predicted in vitro and warrants further clinical study in the treatment of refractory MSSA bacte

175 er compounds allowed us to perform a phase 1 clinical study in which AZD5718 demonstrated a dose depe

176 in a broad range of fundamental and applied clinical studies, including glycan-based biomarker disco

177 However, clinical studies indicate it is dysregulated in neuropsy

178 Clinical studies indicate that antagonizing serotonin (5

179 Clinical studies intended to support regulatory action s

180 To determine whether clinical studies investigating checkpoint molecule expre

181 across the lifespan pave the way for future clinical studies investigating how brain disorders affec

182 ry in patients also paves the way for future clinical studies investigating the added value of post-G

183 A prospective multicenter clinical study involving subjects from 21 sites across t

184 o, the use of (89)Zr-mAbs in preclinical and clinical studies is expanding rapidly.

185 An enduring question from cross-sectional clinical studies is whether the structural and functiona

186 The aim of this prospective, nonrandomized clinical study is to evaluate the possible association o

187 sults as vaccine adjuvant in preclinical and clinical studies, its in vivo stability and potential sy

188 e in vitro Lp-PLA(2) activity assays used in clinical studies may not accurately reflect the residual

189 In phase-1 clinical studies, monotherapy with a single subcutaneous

190 These data support progression into clinical studies (NCT03907969).

191 Certain clinical studies now offer substantial evidence that pro

192 of patients with advanced bladder cancer in clinical studies of 9-ING-41.

193 These results support further clinical studies of a fasting-mimicking diet as an adjuv

194 en applied as a pharmacodynamic parameter in clinical studies of BTK inhibitors.

195 w, we summarize the results of select recent clinical studies of cancer immunotherapies beyond anti-C

196 here can inform crolibulin dosing in future clinical studies of crolibulin combined with cytotoxic o

197 men and support the initiation of additional clinical studies of melflufen in multiple myeloma, both

198 Conduct of preclinical and clinical studies of new therapeutic agents.

199 ing of putative neuroprotectants in enriched clinical studies of patients receiving reperfusion thera

200 ded 5 case-control and 8 other observational clinical studies of SM and UM cases.

201 herapeutic strategies for testing in PD, and clinical studies of some approaches are under way.

202 ere, we review how basic, translational, and clinical studies of the Hedgehog pathway have helped rev

203 se preclinical findings may pave the way for clinical studies of the impact of endurance exercise in

204 Clinical studies of this radiation delivery modality hav

205 esses and failures of recent preclinical and clinical studies of TRAIL-induced apoptosis, and current

206 In clinical studies of TSPO, the ligand total distribution

207 ents with UC treated in the UNIFI phase 3 UC clinical studies of ustekinumab.

208 ing of specific therapies in preclinical and clinical studies of various solid tumors.

209 the Immune Tolerance Network's A Cooperative Clinical Study of Abatacept in Multiple Sclerosis trial

210 myloid deposits is a fundamental task in pre-clinical study of Alzheimer's disease (AD) to assess its

211 Despite extensive clinical study of CA 19-9 in gastrointestinal malignanci

212 In a multisite phase 1 clinical study of crolibulin (NCT00423410), we measured

213 The clinical study of PD-L1 CAR haNKs is warranted.

214 s design and report correctly the results of clinical studies on IOL power calculation and biometry f

215 essment reliability in a blinded, multi-site clinical study on children 18-72 months of age (n = 375)

216 Clinical study on volunteers (n = 33) was performed agai

217 generated and are currently assessed in pre-clinical studies or clinical trials.

218 Despite numerous clinical studies, outcomes are consistently disappointin

219 tching baseline characteristics of the SOLVD clinical study, parameters governing rates of cardiac re

220 sensitivity for IgE-mediated food allergy in clinical study participants who do not undergo OFC.

221 the immune response of influenza vaccines in clinical studies, particularly for the A/H3N2 strain.

222 Clinical studies performed at Duke University Medical Ce

223 Therefore, we evaluated a 'Phase Zero' clinical study platform combining broadband Vis/near-inf

224 In the clinical study, reduced precuneus/posterior cingulate co

225 iew learnings from preclinical modelling and clinical studies relating to the GvT effect, focusing on

226 Although some clinical studies report successful medical stabilization

227 Recent clinical studies reported a higher prevalence of the int

228 Clinical studies reveal changes in blood eosinophil coun

229 e recently emerged; however, preclinical and clinical studies revealed a limited therapeutic time win

230 Further well-designed clinical studies should evaluate the optimal intakes of

231 Clinical studies should reveal if treatment with LP resu

232 Recent clinical studies show a strong association with COVID-19

233 absence of randomised phase 3 trials, early clinical studies show improved survival when radical loc

234 intervertebral disc (IVD) degeneration, but clinical studies show the relationship is complex.

235 Emerging data of clinical studies showed manageable toxicity and safety b

236 Phase 3 clinical studies showed non-inferiority of long-acting i

237 Clinical studies showed that LASER expression is positiv

238 ollowing TBI.SIGNIFICANCE STATEMENT A recent clinical study showed that human brain trauma patients h

239 This prospective clinical study shows no association between endoxifen co

240 estudy serum fatty acid level assessments in clinical studies significantly limit our ability to comp

241 of sample collection for Human Cell Atlas or clinical studies since it increases the time frames for

242 This clinical study sought to define the inflammatory gene an

243 between these events is poorly defined, and clinical studies suggest diminished HIV reactivation in

244 Longitudinal preclinical and clinical studies suggest that Abeta drives neurite and s

245 Pre-clinical studies suggest that Amiodarone induces cytotox

246 Preclinical and clinical studies suggest that inflammation and vascular

247 Preclinical and clinical studies suggest that sphingolipid metabolism al

248 Early clinical studies suggest that topical application of com

249 Over 50 years ago, clinical studies suggested that increases in central ace

250 Our recent clinical study suggested that polyphenol-rich purple pot

251 er of disease state of potential utility for clinical studies targeting psychotic symptoms or as a no

252 cancer is feasible and provides a basis for clinical studies that evaluate early therapeutic interve

253 We also summarize the preclinical and clinical studies that evaluate the potential therapeutic

254 e will discuss evidence from preclinical and clinical studies that gives insights into how the microb

255 o anticipate viral rebound in individuals in clinical studies that include combination antiretroviral

256 is, when possible, was performed to identify clinical studies that investigated predictors of these o

257 earched from inception through 2018/7/15 for clinical studies that investigated the effects of methyl

258 mprehensive search was performed to identify clinical studies that involved soft tissue augmentation

259 summarize the evidence from preclinical and clinical studies that might provide guidance for the dev

260 trol has been underscored by preclinical and clinical studies that observed that T cell presence is p

261 al observations, preclinical experiments and clinical studies that provide evidence for involvement o

262 This paper describes selected analytical and clinical studies that were conducted to evaluate perform

263 serve as a prelude for an adequately powered clinical study that examines the impact of beta-blocker

264 In two clinical studies, the binomialRF algorithm prioritizes p

265 Despite >60 years of preclinical and clinical studies, the immunological requirements necessa

266 pite continued theoretical, preclinical, and clinical study, the mechanism of action remains incomple

267 been used in combination in preclinical and clinical studies, their combined effects on TME are not

268 of results from well designed, large-scale, clinical studies there is considerable variability in th

269 Despite several ongoing clinical studies, there are currently no approved vaccin

270 hibitors of EBV lytic reactivation, and that clinical studies to address critical questions about dis

271 receptors have been developed and tested in clinical studies to evaluate the efficacy of NGF inhibit

272 However, clinical studies to support the claimed health effects o

273 re activity in animal models and are used in clinical studies to treat the negative consequences asso

274 Therefore, we performed a clinical study to elaborate on the implication of CTRPs

275 atients, which we will test in a prospective clinical study, UroPanc.

276 Clinical studies using DCB in de novo coronary artery di

277 vide support for the design of a prospective clinical study using visual function and retinal structu

278 The first clinical studies utilizing RNA-guided endonucleases (RGE

279 A prospective multicenter clinical study was conducted to validate the performance

280 A clinical study was designed to record a wide range of ph

281 The main outcome measure for the clinical study was insulin cessation at 1-year post-surg

282 This prospective clinical study was to compare the effect of panretinal p

283 the present 5-years follow-up retrospective clinical study was to compare the peri-implant soft tiss

284 The purpose of this phase I clinical study was to test the effect of the TVB-2640 in

285 To complement results obtained from clinical studies, we have employed a non-human primate m

286 With the help of a pilot clinical study, we also demonstrate that PulseCam is rob

287 How these challenges were addressed, what clinical studies were conducted during that outbreak, an

288 ul tool for excluding food allergy in future clinical studies where OFC is not conducted.

289 This paper reviews pre-clinical studies, which indicate control of cancer growt

290 While awaiting the results of significant clinical studies, which to date do not exist, the commer

291 Preclinical and clinical studies will examine the systemic effects of en

292 rements and Main Results: We identified nine clinical studies with a total of 863 participants with p

293 ve signatures require training set data from clinical studies with at least two treatment arms.

294 e necessary to optimize the design of future clinical studies with GLA-containing oils.

295 Clinical studies with IL17 and checkpoint blockade repre

296 Clinical studies with larger patient populations that me

297 ngs raise concerns on the design of previous clinical studies with mGlu2/3 agonists, providing the ra

298 sk for the inhibition of OCT1/2 and MATEs in clinical studies with new drug candidates.

299 In a second clinical study with (68)Ga-DOTATATE, we demonstrated com

300 nd Zr complexes under active preclinical and clinical study with as-yet undetermined hydration number